Belfast Telegraph

UK Website Of The Year

Home News Health

New test gives hope more breast cancer patients can avoid chemo

By Jane Kirby

Published 11/07/2016

More women with breast cancer could be spared chemotherapy if doctors switched to a new genetic test, new research has shown. File image
More women with breast cancer could be spared chemotherapy if doctors switched to a new genetic test, new research has shown. File image

More women with breast cancer could be spared chemotherapy if doctors switched to a new genetic test, new research has shown.

The EndoPredict test can more accurately predict whether a woman's cancer will spread around the body than the standard test used on the NHS.

It also can produce results in just a few days compared to around 14 days for the current test, Oncotype DX, which has to be posted to the US.

Both tests provide information about the genetic make-up of a tumour to help predict how cancer might develop over a decade.

This information can be used to identify which patients would be most likely to benefit from treatment with chemotherapy after surgery and those who won't need it - thereby avoiding unnecessary side-effects.

Both tests are for women with oestrogen receptor positive, HER2 negative (ER+/HER2-) disease, which accounts for around two-thirds of all breast cancers.

Over 33,000 women are diagnosed with ER+/HER2- breast cancer each year in the UK.

By identifying those at low risk of their disease spreading, women who would see little benefit from chemotherapy could be spared its gruelling side-effects.

The study - led by researchers at the Institute of Cancer Research in London and the Royal Marsden NHS Foundation Trust in collaboration with Queen Mary University of London, and published in the Journal of the National Cancer Institute - compared the performance of EndoPredict and Oncotype DX.

A woman's risk of her cancer spreading is calculated using the results from the genetic test combined with the size of her tumour and whether disease has spread to the lymph nodes.

In the study, just 5.8% of all patients identified as low risk by EndoPredict went on to see their cancer spread over a decade compared with 10.1% of patients identified as low risk by Oncotype DX.

Study lead author Dr Richard Buus, from the Institute of Cancer Research, London, said: "This study showed that a new test is more accurate than the current NHS standard test at detecting women at lowest risk of their breast cancer spreading.

"It could help improve treatment for a large number of women with breast cancer.

Belfast Telegraph

Read More

From Belfast Telegraph